Outcome is unchanged by adding vincristine upfront to the Malawi 28‐day protocol for endemic Burkitt lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|1545-5009|11|1929-1934

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.1545-5009, Iss.11, 2015-11, pp. : 1929-1934

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Outcome is unchanged by adding vincristine upfront to the Malawi 28‐day protocol for endemic Burkitt lymphoma

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 11, 2015-11 ,pp. : 1929-1934

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 146-153

Karger

Access to resources Recommend Favorite

Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 5, 2015-03 ,pp. : 689-700

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunodeficiency‐associated renal Burkitt lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 769-769

John Wiley & Sons Inc

Access to resources Recommend Favorite

Age‐related heterogeneity of Burkitt lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 153-155

John Wiley & Sons Inc

Access to resources Recommend Favorite